| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 89.0 | 27.5 |
| Gross profit | 81.5 | 24.2 |
| Profit before tax | -0.4 | -34.4 |
| Net income | -1.5 | -33.3 |
| EPS (diluted, $ a share) | $-0.03 | $-0.69 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +223.9% |
|---|---|
| Gross margin | 91.6% |
| Operating margin | 9.4% |
10-Q filed with the SEC, NASDAQ: URGN. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
UroGen Pharma Ltd.: key numbers
- Share price
- $28.10Close, Nov 16
- Market cap
- $1.38B
- Shares outstanding
- 49.05MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from UroGen Pharma Ltd.
All →UroGen Pharma Financial Results
UroGen Pharma reported third-quarter 2026 financial results, highlighted by $68.0 million in ZUSDURI revenue, representing 35% sequential growth. The company also announced that the FDA has accepted its NDA for UGN-103 with a PDUFA goal date of June 14, 2027, and reported a cash position of $215.4 million.
“We delivered another strong quarter of execution, with ZUSDURI continuing to scale as growing repeat utilization, expanding community adoption, and broader physician engagement reinforce our confidence in the long-term commercial opportunity.”
Liz Barrett, President and Chief Executive Officer of UroGen
“The U.S. Food and Drug Administration’s (FDA’s) acceptance of the UGN-103 New Drug Application (NDA) in low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC), together with our newly issued patent providing coverage into July 2044, further reinforce the long-term revenue potential of our bladder cancer portfolio.”
Liz Barrett, President and Chief Executive Officer of UroGen
UroGen Pharma CFO Chris Degnan Sells $80.8K of Stock
Chris Degnan, CFO, sold 2,202 shares of UroGen Pharma Ltd. at $36.69 a share, worth $80.8K in total on Oct 8, 2026. Shares held after the trade: 4,561 (-32.6%).
- Value
- $80.8K
- Shares
- 2,202
- Price
- $36.69
- Role
- CFO
- Holding change
- -32.6%
- Trade date
- Oct 8, 2026